The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
About 5-15% of patients with differentiated thyroid cancer (DTC) primary or within follow-up have had distant metastases or inoperable tumor mass that are resistant to radioiodine therapy as well as dramatically deteriorate survival prognosis. Other treatment modalities (radiotherapy, chemotherapy e...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Endocrinology Research Centre
2015-06-01
|
| Series: | Клиническая и экспериментальная тиреоидология |
| Subjects: | |
| Online Access: | https://cet-endojournals.ru/ket/article/viewFile/7610/5476 |
| _version_ | 1819132125166698496 |
|---|---|
| author | P O Rumyantsev |
| author_facet | P O Rumyantsev |
| author_sort | P O Rumyantsev |
| collection | DOAJ |
| description | About 5-15% of patients with differentiated thyroid cancer (DTC) primary or within follow-up have had distant metastases or inoperable tumor mass that are resistant to radioiodine therapy as well as dramatically deteriorate survival prognosis. Other treatment modalities (radiotherapy, chemotherapy etc.) also ineffective. Certain expectances are associated with target therapy with multikinase inhibitors with are selectively blocking onco-kinase molecular pathways. This review is devoted to analysis of those multikinase inhibitors which have been implemented in patients with radioiodine DTC. Comparative analysis of two most perspective multikinase inhibitors (sorafenib and lenvatinib) with evaluation of efficacy and adverse effects was conducted. Both of them successfully underwent 3 rd phase of clinical trial and were recommended as treatment of choice in progressive radioiodine-resistant DTC patients. |
| first_indexed | 2024-12-22T09:26:25Z |
| format | Article |
| id | doaj.art-5d1a6de97da24a61a17d3309d276f3b4 |
| institution | Directory Open Access Journal |
| issn | 1995-5472 2310-3787 |
| language | Russian |
| last_indexed | 2024-12-22T09:26:25Z |
| publishDate | 2015-06-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Клиническая и экспериментальная тиреоидология |
| spelling | doaj.art-5d1a6de97da24a61a17d3309d276f3b42022-12-21T18:31:04ZrusEndocrinology Research CentreКлиническая и экспериментальная тиреоидология1995-54722310-37872015-06-01112253210.14341/ket2015225-327185The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancerP O Rumyantsev0Endocrinology Research Centre, Moscow, Russian FederationAbout 5-15% of patients with differentiated thyroid cancer (DTC) primary or within follow-up have had distant metastases or inoperable tumor mass that are resistant to radioiodine therapy as well as dramatically deteriorate survival prognosis. Other treatment modalities (radiotherapy, chemotherapy etc.) also ineffective. Certain expectances are associated with target therapy with multikinase inhibitors with are selectively blocking onco-kinase molecular pathways. This review is devoted to analysis of those multikinase inhibitors which have been implemented in patients with radioiodine DTC. Comparative analysis of two most perspective multikinase inhibitors (sorafenib and lenvatinib) with evaluation of efficacy and adverse effects was conducted. Both of them successfully underwent 3 rd phase of clinical trial and were recommended as treatment of choice in progressive radioiodine-resistant DTC patients.https://cet-endojournals.ru/ket/article/viewFile/7610/5476well-differentiated thyroid cancerradioiodine resistancetarget therapymultikinase inhibitorssorafeniblenvatinib |
| spellingShingle | P O Rumyantsev The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer Клиническая и экспериментальная тиреоидология well-differentiated thyroid cancer radioiodine resistance target therapy multikinase inhibitors sorafenib lenvatinib |
| title | The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer |
| title_full | The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer |
| title_fullStr | The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer |
| title_full_unstemmed | The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer |
| title_short | The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer |
| title_sort | role of multikinase inhibitors target therapy in radioiodine resistant differentiated thyroid cancer |
| topic | well-differentiated thyroid cancer radioiodine resistance target therapy multikinase inhibitors sorafenib lenvatinib |
| url | https://cet-endojournals.ru/ket/article/viewFile/7610/5476 |
| work_keys_str_mv | AT porumyantsev theroleofmultikinaseinhibitorstargettherapyinradioiodineresistantdifferentiatedthyroidcancer AT porumyantsev roleofmultikinaseinhibitorstargettherapyinradioiodineresistantdifferentiatedthyroidcancer |